Picture of Precision Biosciences logo

DTIL — Precision Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Precision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary

Precision BioSciences Inc DTIL.OQ reported a quarterly adjusted loss of $2.13​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $4.67.  The mean expectation of four analysts for the quarter was for a loss of $1.57 per share. Wall Street expected results to range from $-2.31 to -9 cents per share.

Revenue fell 100% to $18.00 thousand from a year ago; analysts expected $6.27 million.

Precision BioSciences Inc's reported EPS for the quarter was a loss of $2.13​.

The company reported a quarterly loss of $23.52 million.

Precision BioSciences Inc shares had risen by 14.5% this quarter and gained 26.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4.7% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Precision BioSciences Inc is $21.50, about 77.6% above its last closing price of $4.81

This summary was machine generated from LSEG data August 7 at 06:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
Jun. 30 2025-1.57-2.13Missed
Mar. 31 2025-1.72-2.21Missed
Dec. 31 2024-1.96-2.22Missed
Sep. 30 2024-1.92-2.25Missed

Recent news on Precision Biosciences

See all news